VRNA Valuation

Verona Pharma PLC

Add to Watchlist

Advanced Chart

105.560

+0.11(0.104%)1D

Overview
Forecast
Valuation
Earnings

VRNA Relative Valuation

VRNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRNA is overvalued; if below, it's undervalued.

Historical Valuation

Verona Pharma PLC (VRNA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 16.25 is considered Undervalued compared with the five-year average of -67.10. The fair price of Verona Pharma PLC (VRNA) is between 128.04 to 288.53 according to relative valuation methord. Compared to the current price of 105.62 USD , Verona Pharma PLC is Undervalued By 17.51%.

Relative Value

Fair Zone

128.04-288.53

Current Price：105.62

17.51%

Undervalued

65.60

Trailing

Forward

0.00

EV/EBITDA

Verona Pharma PLC. (VRNA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -11.13. The thresholds are as follows: Strongly Undervalued below -80.51, Undervalued between -80.51 and -45.82, Fairly Valued between 23.56 and -45.82, Overvalued between 23.56 and 58.24, and Strongly Overvalued above 58.24. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

58.17

EV/EBIT

Verona Pharma PLC. (VRNA) has a current EV/EBIT of 58.17. The 5-year average EV/EBIT is -4.19. The thresholds are as follows: Strongly Undervalued below -108.41, Undervalued between -108.41 and -56.30, Fairly Valued between 47.92 and -56.30, Overvalued between 47.92 and 100.03, and Strongly Overvalued above 100.03. The current Forward EV/EBIT of 58.17 falls within the Overvalued range.

16.34

Verona Pharma PLC. (VRNA) has a current PS of 16.34. The 5-year average PS is 77.09. The thresholds are as follows: Strongly Undervalued below -206.07, Undervalued between -206.07 and -64.49, Fairly Valued between 218.67 and -64.49, Overvalued between 218.67 and 360.25, and Strongly Overvalued above 360.25. The current Forward PS of 16.34 falls within the Historic Trend Line -Fairly Valued range.

311.42

P/OCF

Verona Pharma PLC. (VRNA) has a current P/OCF of 311.42. The 5-year average P/OCF is 31.20. The thresholds are as follows: Strongly Undervalued below -239.41, Undervalued between -239.41 and -104.11, Fairly Valued between 166.50 and -104.11, Overvalued between 166.50 and 301.81, and Strongly Overvalued above 301.81. The current Forward P/OCF of 311.42 falls within the Strongly Overvalued range.

347.59

P/FCF

Verona Pharma PLC. (VRNA) has a current P/FCF of 347.59. The 5-year average P/FCF is 33.84. The thresholds are as follows: Strongly Undervalued below -289.27, Undervalued between -289.27 and -127.71, Fairly Valued between 195.39 and -127.71, Overvalued between 195.39 and 356.94, and Strongly Overvalued above 356.94. The current Forward P/FCF of 347.59 falls within the Overvalued range.

Verona Pharma PLC (VRNA) has a current Price-to-Book (P/B) ratio of 32.69. Compared to its 3-year average P/B ratio of 12.56 , the current P/B ratio is approximately 160.36% higher. Relative to its 5-year average P/B ratio of 8.43, the current P/B ratio is about 288.04% higher. Verona Pharma PLC (VRNA) has a Forward Free Cash Flow (FCF) yield of approximately -0.81%. Compared to its 3-year average FCF yield of -3.31%, the current FCF yield is approximately -75.57% lower. Relative to its 5-year average FCF yield of -6.13% , the current FCF yield is about -86.80% lower.

32.59

P/B

Median3y

12.56

Median5y

8.43

-0.81

FCF Yield

Median3y

-3.31

Median5y

-6.13

Competitors Valuation Multiple

The average P/S ratio for VRNA's competitors is 59.25, providing a benchmark for relative valuation. Verona Pharma PLC Corp (VRNA) exhibits a P/S ratio of 16.34, which is -72.43% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Madrigal Pharmaceuticals Inc

Corcept Therapeutics Inc

7.22

18.70%

7.41B

Performance Decomposition

Market capitalization of VRNA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of VRNA in the past 1 year is driven by Unknown.